ICI ICI SEES GROWTH IN PHARMACEUTICALS LOS ANGELES March Imperial Chemical Industries PLC expects earnings from its pharmaceuticals operations to grow to about pct of world profits within the next five years compared with a current pct chairman elect Denys Henderson told financial analysts Over the next five years we expect to launch one major new product each year Henderson said He also said research and development spending in this business segment will be increased to pct of total sales income in from pct or mln sterling in ICI the world s fifth largest chemicals firm in terms of sales recently reported profits of about mln dlrs on billion dlrs in sales compared with income of mln dlrs on billion dlrs in sales a year earlier Sales in the United States totaled about three billion dlrs ICI executives said In addition Henderson said overall corporate growth will come from ICI s research and development activities but the company intends to continue to grow through an acquisition program ICI spent just under one billion dlrs for acquisitions during the largest of which was the mln dlr purchase of Cleveland Ohio based Glidden Inc a paints resins and coatings company from Hanson Trust PLC ICI financial director Alan Clements said the company s borrowing limits are at a level of about billion sterling billion of which have already been used While the company has no current plans for a major acquisition we are ready to move quickly in the acquisition field if the need arises Clements said Reuter